PlainPill

Nicotinic Acid

People mainly take Nicotinic Acid for energy, anxiety, mood. Based on 13 first-hand reports and 32 meta-analyses & systematic reviews in the medical literature. Ranked #455 of 1,974 overall.

28
User score
Mostly positive
38% positive23% mixed0% negative38% unclear

Of reports that state an outcome, 62% are positive.

Clinical research
AStrong research base
32
meta-analyses
143
RCTs
12,391
papers

What Nicotinic Acid does, according to users

Of the people who reported each effect, the share who said it got better.

2 more with fewer than 3 reports
betterno changeworse

What the research says

Systematic reviews and meta-analyses from PubMed, with their published conclusions.

AStrong research base

3+ meta-analyses or systematic reviews and 10+ randomized controlled trials in humans. The grade measures how much human research exists — read the conclusions below for what it found.

BMJ Clin Evid · 2010 · Meta-analysis / systematic review
Primary prevention of CVD: treating dyslipidaemia

Conclusion: In this systematic review we present information relating to the effectiveness and safety of the following interventions: ezetimibe, fibrates, niacin (nicotinic acid), reduced- or modified-fat diet, resins, and statins.

PubMed 21418693 ↗
Atherosclerosis · 2010 · Meta-analysis / systematic review
Meta-analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosis

Conclusion: Although the studies were conducted before statin therapy become standard care, and mostly in patients in secondary prevention, with various dosages of nicotinic acid 1-3g/day, this meta-analysis found positive effects of niacin alone or in combination on all cardiovascular events and on atherosclerosis evolution.

PubMed 20079494 ↗
BMJ Clin Evid · 2008 · Meta-analysis / systematic review
Diabetes: managing dyslipidaemia

Conclusion: In this systematic review we present information relating to the effectiveness and safety of the following interventions: anion exchange resins, combined treatments (for lipid modification), ezetimibe, fibrates, fish oil (for lipid modification), intensive multiple intervention treatment programmes (for lipid modification), nicotinic acid (for lipid modification), and statins.

PubMed 19450295 ↗
Exp Gerontol · 2020 · Meta-analysis / systematic review
NAD+ therapy in age-related degenerative disorders: A benefit/risk analysis

Conclusion: Potential risks in raising NAD+ levels in various clinical disorders using NAD+ precursors include the accumulation of putative toxic metabolites, tumorigenesis and promotion of cellular senescence. Therefore, NAD+ metabolism represents a promising target and further studies are needed to recapitulate the preclinical benefits in human clinical trials.

PubMed 31917996 ↗

Dosage people report

As stated by users — not a recommendation. Follow the label or your doctor.

dailyas reported
1000 mgas reported
500 mg (formerly), now 100 mg or belowas reported
500 mgas reported

Reported side effects

How often each side effect came up across all reports.

peripheral neuropathy ×1leg pain ×1leg weakness ×1

What users say

Verbatim quotes, shortened only — each links to the original discussion.

“take vitamin D and nicotinic acid supplements. Nicotinic acid will help convert tryptophan to serotonin much more effectively”
Source discussion ↗
“Some of the lower cost ones I really value include: Nicotinic Acid (more so than any other NMN precursor)”
Source discussion ↗
“Nicotinic Acid for NAD production and peripheral blood circulation boost”
Source discussion ↗
“I developed a severe form of peripheral neuropathy - small fiber. I've been through hell.”
Source discussion ↗
“taking histamine-increasing supplements like Zinc, L-Histidine, Manganese, Nicotinic Acid and Vitamin C.”
Source discussion ↗
Top discussions (5)

Other options for energy

User data from public discussions; research from PubMed. Information only, not medical advice — talk to a doctor before starting, stopping or combining anything. Data updated October 2, 2026. How we rate